KNCN: A Protein Involved in Inflammation and Autoimmune Diseases

Target Name: KNCN

NCBI ID: G148930

KNCN

KNCN: A Protein Involved in Inflammation and Autoimmune Diseases

KNCN (Kalbinden-Nasledal) is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and pancreas. It is a member of the Kallikrein family of proteins, which are involved in the regulation of complement proteins.

KNCN is known for its role in the regulation of inflammation and autoimmune diseases. It has been shown to play a key role in the development and progression of several diseases, including autoimmune neurodegenerative diseases, such as multiple sclerosis and amyloidosis.

KNCN has also been shown to be involved in the regulation of pain perception and neuroinflammation. It has been shown to interact with several neurotransmitters, including GABA, MAP, and TrkA.

KNCN has also been shown to be involved in the regulation of cell survival and proliferation. It has been shown to play a role in the regulation of cell apoptosis, and has been shown to promote the survival of certain cancer cell lines.

KNCN has also been shown to be involved in the regulation of the immune response. It has been shown to interact with several immune cell types, including T cells and B cells.

KNCN has also been shown to be involved in the regulation of inflammation and autoimmune diseases. It has been shown to play a key role in the development and progression of several diseases, including autoimmune neurodegenerative diseases, such as multiple sclerosis and amyloidosis.

In addition to its role in the regulation of inflammation and autoimmune diseases, KNCN has also been shown to have potential as a drug target. Several studies have shown that KNCN can be targeted by small molecules, including inhibitors of the protein kinase CKL (KLF1) , a known regulator of KNCN, and by inhibitors of its downstream target, p38 MAPK (PYK38).

KNCN has also been shown to have potential as a biomarker for several diseases, including cancer. Several studies have shown that KNCN levels can be increased in several types of cancer, including breast, ovarian, and colorectal cancer.

Overall, KNCN is a protein that has the potential to be a drug target or biomarker for several diseases. Further research is needed to fully understand its role in the regulation of inflammation and autoimmune diseases, and to determine its potential as a drug.

Protein Name: Kinocilin

Functions: May play a role in stabilizing dense microtubular networks or in vesicular trafficking

The "KNCN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KNCN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets